

# Selvita Newsletter

*Selvita's newsletter is published quarterly by Selvita's sales&marketing team, with the purpose of updating our current and prospective clients on the most important developments within the company.*

## NEWS


---

### BIOCENTRUM OBTAINS A GLP CERTIFICATE

On 19 May 2011, BioCentrum, part of the Selvita Group, received a certificate of compliance with the principles of Good Laboratory Practice (GLP). Awarded GLP Certificate covers all the activities of the BioCentrum's Cell Laboratory, including analytical and clinical chemistry testing, as well as *in vitro* tests in the area of cytotoxicity of chemical substances. This certificate has been issued for an indefinite period of time, however its subject to compulsory re-certification in 2 years from the date of the issue.

GLP certification marks a very important step in the company's development. It provides evidence that BioCentrum applies the highest standards of quality in all the work and services performed.

[→ Read more in the press release](#)



### SELVITA VOTED THE MOST INNOVATIVE BIOTECH COMPANY IN CEE

During this year's edition of the "Masters of Innovation" competition, organized along with the Central European Forum of Biotechnology and Innovative BioEconomy - BioForum 2011, Selvita was voted the most innovative biotechnology company in the region.

The participants of the competition were the most innovative enterprises from the biotech sector in the Eastern and Central European region. The main criterion for the evaluation of participants were the R&D projects run by a company and their innovation. Additionally, the business model, and aspects such as how effectively a company finds opportunities to finance its' research and development activities and its implementation, were also assessed.

[→ Read more in the press release](#)

## COME AND MEET US

---

**20 - 21 JULY 2011** – BIO  
DEUTSCHLAND – Hamburg,  
Germany

**7 - 9 SEPTEMBER 2011** –  
BIOPHARM AMERICA 2011 –  
Boston, USA

## MEDIA ABOUT US

---

[SELVITA FEATURED IN BIOTECH  
FINANCE](#)

*Biotech Finance no. 507*

## **SELVITA COMPLETES A ROUND OF PRIVATE PLACEMENT AND GOES PUBLIC ON THE WARSAW STOCK EXCHANGE MARKET**

In May 2011, Selvita has entered into a definitive agreements with investors in Poland to sell in a private placement 2,7 million shares of its stock at a price of PLN 5.5 per share, resulting in gross proceeds to the company of PLN 14,85 million (\$ 5.5 million). The capitalization of the company after the issue is around \$ 21 million.

Following this event, Selvita's stock was listed on the Warsaw Stock Exchange NewConnect market on July 14, under the ticker SLV.

Proceeds from the financing will be used primarily for the ongoing pre-clinical development of Selvita's drug candidates including the potentially first in class compounds: SEL24 (Pim kinase inhibitor in oncology), SEL120 (anti-mitotic agent with a novel mechanism of action) and SEL113 (oncology and auto-immune disorders). The company will also expand its lab space for outsourcing of drug discovery projects which is the second pillar of Selvita's business model.

[→ Read more in the press release](#)



## **NEW DEALS & COLLABORATIONS**

### **INITIATION OF THE VACIMMUNE PROJECT**

Selvita has signed an agreement with the National Center for Research and Development, which is the Polish coordinator of the program EUROSTARS, initiating the VACIMMUNE project.

The main objective of the project is to conduct research leading to generation of an anti-human antibody FCGR2B for use in vaccines for eg. multiple sclerosis.

VACIMMUNE project is implemented under the program EUROSTARS - European Program for research and technological development, dedicated to projects which aim to develop a new product, service or process.

The consortium implementing the project, in addition to Selvita, contains of two foreign partners: Immunaffect BV-coordinator of the project and VU Medish Centre. In this project, Selvita will be responsible for developing a methodology for modeling antibody-antigen systems, preparation and implementation of computer software, as well as optimization of the designed antibodies.

## **FOLLOW US ON**



twitter



### **CONTACT DETAILS:**

sales@selvita.com  
www.selvita.com

Selvita S.A.  
Bobrzynskiego 14  
30-348 Krakow  
Poland